In 2014, 91% of Swedish men with very low risk prostate cancer opted for active surveillance.
Labeling information will include data showing the drug reduces the risk of radiographic progression versus bicalutamide.
Smokeless tobacco "snus" users have high blood levels of nicotine which promotes cancer progression.
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
The risk of dementia was 2-fold higher among ADT users.
A phase 3 study of ipilimumab among patients with metastatic, castration-resistant prostate cancer (mCRPC) did not meet its primary endpoint.
NEPC is an aggressive subtype of castration-resistant prostate cancer independent of androgen expression.
A body mass index of 30 kg/m2 or higher was was associated with 2-fold increased risk of dying from prostate cancer.
Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.
Pooled analysis shows initial use of degarelix versus LHRH agonists was associated with improved PSA progression-free survival.
In a study, a drop in alkaline phosphatase level at 12 weeks compared with baseline was associated with a decreased risk of death and first symptomatic skeletal event.
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Metastasis-free survival correlates with overall survival in localized prostate cancer clinical trials.
Over a median follow-up of 70 months, 15% of men studied experienced biochemical recurrence.
Within each D'Amico risk category, African-American and Hispanic prostate cancer patients were less likely to receive definitive treatment than white patients.
Two new equations could better descriminate between clinical significant and indolent prostate cancer
Results show that mpMRI and PI-RADSv2 score have a greater ability to detect prostate cancer progression after TRT compared with PSA.
Addition of external beam therapy doesn't improve 5-year progression-free survival in prostate cancet
Data from 21 observational studies showed an 8% increased risk of prostate cancer.
Medicine is making progress to refine patient care.
The approach can help identify suitable candidates for active surveillance, but false positives and cost effectiveness are concerns.
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Ten-year mortality rates of prostate cancer are low, regardless of whether patients are treated with radiotherapy, surgery, or undergo only active surveillance.
Large study challenges previous research linking the procedure to slightly higher chance of disease.
Urinary, bowel, sexual function, and quality of life among men with prostate cancer may vary depending on treatment type.
Clinicians now have tools for improving prostate cancer screening and risk stratification.
Researchers' results showed that the presence of a urinary catheter and recent antibiotic use were associated with increased odds of intra-operative bacteremia.
Study tested the combination in men with treatment-naïve prostate cancer and bone metastasis.
Findings among men with localized intermediate- and high-risk prostate cancer.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)